Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics

Eagle Pharmaceuticals, Inc. (EGRX): $27.10

0.41 (+1.54%)

POWR Rating

Component Grades














  • Value is the dimension where EGRX ranks best; there it ranks ahead of 99.75% of US stocks.
  • EGRX's strongest trending metric is Quality; it's been moving down over the last 178 days.
  • EGRX's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

EGRX Stock Summary

  • With a year-over-year growth in debt of 123.33%, EAGLE PHARMACEUTICALS INC's debt growth rate surpasses 89.62% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, EAGLE PHARMACEUTICALS INC is reporting a growth rate of 612.89%; that's higher than 97.14% of US stocks.
  • As for revenue growth, note that EGRX's revenue has grown 66.48% over the past 12 months; that beats the revenue growth of 88.7% of US companies in our set.
  • Stocks that are quantitatively similar to EGRX, based on their financial statements, market capitalization, and price volatility, are GLBE, WEAV, RCEL, FLYW, and VBIV.
  • Visit EGRX's SEC page to see the company's official filings. To visit the company's web site, go to www.eagleus.com.

EGRX Valuation Summary

  • In comparison to the median Healthcare stock, EGRX's EV/EBIT ratio is 11.45% higher, now standing at 7.3.
  • Over the past 111 months, EGRX's price/sales ratio has gone down 9.

Below are key valuation metrics over time for EGRX.

Stock Date P/S P/B P/E EV/EBIT
EGRX 2023-03-17 1.1 1.4 15.7 7.3
EGRX 2023-03-16 1.2 1.5 16.2 7.5
EGRX 2023-03-15 1.1 1.4 15.8 7.4
EGRX 2023-03-14 1.1 1.4 15.7 7.3
EGRX 2023-03-13 1.1 1.4 15.6 7.3
EGRX 2023-03-10 1.1 1.4 15.3 7.2

EGRX Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -6.3%.
  • Its 2 year price growth rate is now at -21.29%.
  • Its 2 year revenue growth rate is now at 28.13%.
Over the past 67 months, EGRX's revenue has gone up $61,546,000.

The table below shows EGRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 298.231 21.225 21.281
2022-06-30 272.183 35.529 22.79
2022-03-31 246.171 1.13 35.852
2021-12-31 171.546 28.219 -8.627
2021-09-30 179.142 39.898 5.626
2021-06-30 189.217 44.458 18.307

EGRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EGRX has a Quality Grade of B, ranking ahead of 92.42% of graded US stocks.
  • EGRX's asset turnover comes in at 0.738 -- ranking 36th of 682 Pharmaceutical Products stocks.
  • ACUR, XENE, and KMPH are the stocks whose asset turnover ratios are most correlated with EGRX.

The table below shows EGRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.738 0.756 0.315
2021-03-31 0.719 0.735 0.316
2020-12-31 0.671 0.758 0.264
2020-09-30 0.664 0.761 0.184
2020-06-30 0.628 0.732 0.068
2020-03-31 0.677 0.711 0.109

EGRX Price Target

For more insight on analysts targets of EGRX, see our EGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.50 Average Broker Recommendation 1.67 (Moderate Buy)

EGRX Stock Price Chart Interactive Chart >

Price chart for EGRX

EGRX Price/Volume Stats

Current price $27.10 52-week high $52.22
Prev. close $26.69 52-week low $23.87
Day low $26.51 Volume 103,626
Day high $27.50 Avg. volume 165,725
50-day MA $30.05 Dividend yield N/A
200-day MA $34.04 Market Cap 352.73M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio

Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.

EGRX Latest News Stream

Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream

Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about EAGLE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Call Transcript

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good morning, everyone. My name is Todd, and I’ll be your conference operator. At this time, I’d like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results . All lines have been placed on mute to prevent any […]

Yahoo | March 14, 2023

Q4 2022 Eagle Pharmaceuticals Inc Earnings Call

Q4 2022 Eagle Pharmaceuticals Inc Earnings Call

Yahoo | March 14, 2023

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 13, 2023

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled

Yahoo | March 13, 2023

Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference

WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows: Date:Wednesday, March 15, 2023 Time:2:35pm ETWebcast:Click Here To schedule a 1x1 meeting, please contact your Barclays representative. About Eagle Pharmaceutica

Yahoo | March 9, 2023

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo -12.01%
3-mo -9.27%
6-mo -0.11%
1-year -44.61%
3-year -26.50%
5-year -49.11%
YTD -7.29%
2022 -42.60%
2021 9.34%
2020 -22.49%
2019 49.12%
2018 -24.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8921 seconds.